Funding for this research was provided by:
Swedish Orphan Biovitrum (222586)
Immedica Pharma AB (356654)
Article History
Received: 15 February 2021
Accepted: 11 October 2021
First Online: 25 October 2021
Declarations
:
: Ethical approval was obtained from Manchester Metropolitan University Faculty Ethics Committee, UK (Ref: 10306). Participants were presented with a participant information sheet to consider prior to indicating their consent. Completed consent forms have been retained by the research team.
: Not applicable.
: The authors declare that this study was funded by Swedish Orphan Biovitrum (SOBI) pharmaceutical, the company that was authorised to distribute Ravicti (GPB) at the time when the study was conducted. The writing of this manuscript was funded by Immedica Pharma AB, the company who is currently the marketing-authorisation holder of Ravicti (GPB).